About: Clinical course and treatment efficacy of COVID‐19 near Hubei Province, China: a multicentre, retrospective study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical course and treatment efficacy of COVID‐19 near Hubei Province, China: a multicentre, retrospective study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Clinical course and treatment efficacy of COVID‐19 near Hubei Province, China: a multicentre, retrospective study
Creator	Wang, S Chen, L Gao, F Lin, M Wang, M Wei, L Wei, T Xie, L Chang, S Yao, L Bai, Y Cruz, Dela Mack, C Sharma, C Zhu, G Cao, C Carlos, W Channappanavar, L Critical Care Trial, G Fett, R Hayden, P Horby, C Jama, C Jamil, S Jin, D Meyerholz, P Pasnick, B Perlman, D Ten Eyck, M Tian, F
Source	Medline; PMC
abstract	Currently, COVID‐19 has been reported in nearly all countries globally. To date, little is known about the viral shedding duration, clinical course, and treatment efficacy of COVID‐19 near Hubei Province, China. This multicentre, retrospective study was performed in 12 hospitals in Henan and Shaanxi Provinces from January 20 to February 8, 2020. Clinical outcomes were followed up until March 26, 2020. The viral shedding duration, full clinical course, and treatment efficacy were analysed in different subgroups of patients. A total of 149 COVID‐19 patients were enrolled. The median age was 42 years, and 61.1% (91) were males. Of them, 133 (89.3%) had fever, 131 of 144 (91%) had pneumonia, 27 (18.1%) required intensive care unit (ICU) management, 3 (2%) were pregnant, and 3 (2%) died. Two premature newborns were negative for SARS‐CoV‐2. In total, the median SARS‐CoV‐2 shedding period and clinical course were 12 (IQR: 9‐17; mean: 13.4, 95% CI: 12.5, 14.2) and 20 (IQR: 16‐24; mean: 21.2, 95% CI: 20.1, 22.3) days, respectively; and ICU patients had longer median viral shedding periods (21 [17‐24] vs 11 [9‐15]) and clinical courses (30 [22‐33] vs 19 [15.8‐22]) than non‐ICU patients (both p<0.0001). SARS‐CoV‐2 clearances occurred at least 2 days before fatality in 3 non‐survivors. Current treatment with any antiviral agent or combination did not present the benefit of shortening viral shedding period and clinical course (all p>0.05) in real‐life settings. In conclusion, the viral shedding duration and clinical course in Henan and Shaanxi Provinces were shorter than those in Hubei Province, and current antiviral therapies were ineffective for shortening viral shedding duration and clinical course in real‐world settings. These findings expand our knowledge of the SARS‐CoV‐2 infection and may be helpful for management of the epidemic outbreak of COVID‐19 worldwide. Further studies concerning effective antiviral agents and vaccines are urgently needed.
has issue date	2020-06-12(xsd:dateTime)
bibo:doi	10.1111/tbed.13674
bibo:pmid	32531138
has license	no-cc
sha1sum (hex)	5b3a5a9508eb52f7e0c740104d3c9a62702e5698
schema:url	https://doi.org/10.1111/tbed.13674
resource representing a document's title	Clinical course and treatment efficacy of COVID‐19 near Hubei Province, China: a multicentre, retrospective study
has PubMed Central identifier	PMC7307118
has PubMed identifier	32531138
schema:publication	Transbound Emerg Dis
resource representing a document's body	covid:5b3a5a9508eb52f7e0c740104d3c9a62702e5698#body_text
is schema:about of	named entity 'median age' named entity 'clearances' named entity 'therapies' named entity 'outbreak' named entity 'family' named entity 'males' named entity 'shortening' named entity 'Infections' named entity 'SURVIVORS' named entity 'PREGNANT' named entity 'CLUSTER' named entity 'OUTBREAK' named entity 'NEGATIVE' named entity 'TREATMENT EFFICACY' named entity 'OCCURRED' named entity 'HUBEI PROVINCE' named entity 'VIRAL SHEDDING' named entity 'IQR' named entity 'coronavirus' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'vaccines' named entity 'copyright' named entity 'antiviral agents' named entity 'study' named entity 'shorter' named entity 'efficacy' named entity 'pneumonia' named entity 'Lancet' named entity 'SARS-CoV-2' named entity 'Clinical outcomes' named entity 'Shaanxi' named entity 'IQR' named entity 'antiviral agents' named entity 'ICU' named entity 'China' named entity 'helpful' named entity 'denaturation' named entity 'negative result' named entity 'comorbidities' named entity 'WHO' named entity 'electronic medical records' named entity 'pneumonia' named entity 'COVID-19' named entity 'fever' named entity 'Hubei Province' named entity 'Hubei Province, China' named entity 'chronic liver' named entity 'SARS-CoV-2' named entity 'Henan Province' named entity 'chronic liver' named entity 'RNA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software